Repositioning Candidate Details
| Candidate ID: | R0717 |
| Source ID: | DB05142 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | ND7001 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in anxiety disorders and depression. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Phosphodiesterase 2A, cGMP-stimulated; cGMP-dependent 3',5'-cyclic phosphodiesterase |
| Inclusion Criteria: | Indication associated |
